The JAVELIN Bladder 100 trial demonstrated that avelumab plus best supportive care prolonged overall survival vs best supportive care alone for patients with advanced urothelial carcinoma.
Three year follow-up findings from a post hoc analysis of the phase 3 ARAMIS trial indicated that darolutamide maintained a survival benefit regardless of prior local therapy for patients with nonmetastatic castration-resistant prostate cancer.
Adding niraparib to abiraterone acetate and prednisone improved efficacy and yielded tolerable safety for patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations.
Patients with upper tract urothelial carcinoma may benefit from treatment with oral FGFR1-3 inhibitor infigratinib.
Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.
Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.
Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.
The CALGB prognostic risk group and subsequent life-prolonging therapies could potentially impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.
Patients with low-grade upper tract urothelial carcinoma achieved a long period of durable response after undergoing treatment with UGN-101.
Yoga not only yields improvements in physical, mental, and sexual wellbeing, but it may also result in reduced inflammation and antitumor responses in men with prostate cancer.